Search alternatives:
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a mean » _ mean (Expand Search)
Showing 1,141 - 1,160 results of 118,456 for search '(( a mean decrease ) OR ( 5 ((wt decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.57s Refine Results
  1. 1141
    TH588 effectively decreases cellular survival in heterogeneous neuroendocrine tumor cells.

    TH588 effectively decreases cellular survival in heterogeneous neuroendocrine tumor cells. by Elke Tatjana Aristizabal Prada (833927)

    Published 2017
    Save to List
    Saved in:
  2. 1142
    Effects of FE and RUD wrist postures on the mean carpal tunnel depth within each quartile.

    Effects of FE and RUD wrist postures on the mean carpal tunnel depth within each quartile. by Drew A. Anderson (14197446)

    Published 2022
    Save to List
    Saved in:
  3. 1143
    Effects of FE and RUD wrist postures on the mean carpal tunnel width within each quartile.

    Effects of FE and RUD wrist postures on the mean carpal tunnel width within each quartile. by Drew A. Anderson (14197446)

    Published 2022
    Save to List
    Saved in:
  4. 1144
    Effects of FE and RUD wrist postures on the mean cross-sectional area within each quartile.

    Effects of FE and RUD wrist postures on the mean cross-sectional area within each quartile. by Drew A. Anderson (14197446)

    Published 2022
    Save to List
    Saved in:
  5. 1145
    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort

    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

    Published 2014
    Save to List
    Saved in:
  6. 1146
    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells.

    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

    Published 2013
    Save to List
    Saved in:
  7. 1147
    Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation

    Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation by Yaowaluk Tariwong (22630109)

    Published 2025
    Save to List
    Saved in:
  8. 1148
    ALK<sup>wt</sup>–ABT199 interactions.

    ALK<sup>wt</sup>–ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Save to List
    Saved in:
  9. 1149
    P-Rex is required for a late phase of stimulus-evoked cerebellar LTP.

    P-Rex is required for a late phase of stimulus-evoked cerebellar LTP. by Claire Jackson (362873)

    Published 2010
    Save to List
    Saved in:
  10. 1150
    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis.

    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  11. 1151
    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis.

    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  12. 1152
    eNOS phosphorylation increased intracellular ROS generation and decreased cell viability in BH4-depleted cells.

    eNOS phosphorylation increased intracellular ROS generation and decreased cell viability in BH4-depleted cells. by Hu Peng (396074)

    Published 2015
    “…<p>(A) HEK 293 cells were treated with DMSO or 10mM DAHP for 24 hours to deplete BH4, then transfected with either control vector or WT eNOS plasmid DNA overnight. …”
    Save to List
    Saved in:
  13. 1153
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 1154
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 1155
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 1156
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 1157
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 1158
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 1159
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 1160
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: